🏛️ Verified NIH Record • Updated 2025-09-22

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial (NCT04883671)

🟢 Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: Dana-Farber Cancer Institute

🩺 Plain-English Summary (8th-Grade Level)

The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (26 items) and avoid the listed exclusions (12 items).

Location: University of California, San Francisco — San Francisco, California

Age range: 18 Years

🧪 Interventions in This Study

  • Standard of Care (OTHER)
  • SBRT (RADIATION)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Cohort 1
  • Subject who has received systemic therapy for treatment of ACC within 2 weeks of enrollment.
  • Evidence of need for urgent surgical intervention for metastatic CNS or spine disease.
  • Cohort 1
  • Alternative locally ablative therapies received (radiofrequency ablation, cryotherapy, or \[chemo\]embolization) for any metastatic foci planned for SBRT at the time of study enrollment that precludes administration of SBRT.
  • Bone metastasis in a femoral bone for which surgical stabilization is recommended.
  • Cohort 1
  • Active disease \>1 cm that is progressing and not amenable to SBRT.
  • Pregnant or lactating women.
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions: include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, and low-risk prostate adenocarcinoma being managed with active surveillance. A history of another separate malignancy in remission without evidence of active disease in the last 2 years is permitted.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (5 Sites)

  • University of California, San Francisco — San Francisco, California
  • University of Chicago — Chicago, Illinois
  • Brigham and Women's Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
  • MD Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (617) 632-5296

Email: jonathan_schoenfeld@dfci.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Adenoid Cystic Carcinoma

Explore by condition: All Adenoid Cystic Carcinoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗